Search Within

Theresa Davey

Formats
  1. Meeting Abstract (22)
  2. Journal Article (4)
Groups
  1. Advanced Practice Providers (26)
  2. Center for Hematologic Malignancies (26)
  3. Department of Medicine (26)
  4. Hematologic Malignancies, Division of (26)
  5. Lymphoma (26)
  6. Population Sciences Research Program (25)

More Groups

People
  1. Alison Moskowitz (26)
  2. Steven Horwitz (25)
  3. Helen Hancock (24)
  4. Nivetha Ganesan (22)
  5. Natasha Galasso (21)
  6. Ahmet Dogan (17)

More People

Years
  1. 2025 (1)
  2. 2024 (6)
  3. 2023 (5)
  4. 2022 (1)
  5. 2021 (4)
  6. 2020 (2)

More Years

Publications
  1. Blood (18)
  2. Hematological Oncology (4)
  3. Journal of Clinical Oncology (2)
  4. Cancer Research (1)
  5. Nature Medicine (1)
Publishers
  1. American Society of Hematology (18)
  2. Wiley Blackwell (4)
  3. American Society of Clinical Oncology (2)
  4. American Association for Cancer Research (1)
  5. Nature Publishing Group (1)

Results (26)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Final results of a phase II biomarker-driven study of ruxolitinib in relapsed and refractory T-cell lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E. D.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Hancock, H.; Davey, T.; Obadi, O.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • A phase II, multicenter study of high dose chemotherapy with autologous stem cell transplant followed by maintenance therapy with romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Shustov, A. R.; Khimani, F.; Shadman, M.; Cassaday, R. D.; Ruan, J.; Moskowitz, A. J.; Zelenetz, A. D.; Noy, A.; Straus, D. J.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • The combination of duvelisib, a PI3K-δ,γ inhibitor, and romidepsin is highly active in relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: Results of parallel multicenter, phase 1 combination studies with expansion cohorts
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Jacobsen, E. D.; Mehta-Shah, N.; Khodadoust, M. S.; Fisher, D. C.; Myskowski, P.; Wang, E. B. K.; Tawa, M.; Davey, T.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Durable responses observed with JAK inhibition in T-cell lymphomas
    Meeting Abstract

    Moskowitz, A. J.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Obadi, O.; Motylinski, K.; Jarjies, C.; Galasso, N.; Hancock, H.; Davey, T.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-δ,γ inhibitor, in combination with romidepsin or bortezomib in relapsed/refractory T-cell lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Koch, R.; Mehta-Shah, N.; Myskowski, P.; Kheterpal, M.; Dogan, A.; Davey, T.; Galasso, N.; Evan, M.; Shah, M.; more...
    Blood (2017)

    Fulltext@MSK | Save